This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Pancreatic ductal adenocarcinoma (PDAC) has shown highly elevated repeat RNA expression in both mouse models and human tumors (), the majority of which are non-coding RNAs that have demonstrated the ...

AbstractPurpose:. Targeted tumor delivery may be required to potentiate the clinical benefit of innate immune modulators. The objective of the study was to apply an antibody–drug conjugate (ADC) ...

Cancer cells exhibit a characteristic metabolic pattern known as the Warburg effect, which upregulates glycolysis even in aerobic environments. As a result, cancer cells are exposed to an acidic ...

In patients with non–small cell lung cancer (NSCLC), the relationship between tumor metabolism and clinical outcomes is unknown. Here, 13 C-labeled nutrients were intraoperatively infused into more ...

We evaluate cancer-protective effects of walnuts via formation of microbe-derived urolithin A, substantiating their functional benefits on serum inflammatory markers and immunologic composition of ...

Aberrant activation of ERBB family members through various mechanisms plays a crucial role in the development and progression of a variety of cancer types ().Overexpression of HER2, due to ERBB2 ...

Androgen deprivation therapy is the standard of care for patients with metastatic disease, which eventually leads to the development of castration-resistant prostate cancer (CRPC) that limits androgen ...

A promising new treatment option for TNBC is adoptive T-cell therapy (ACT). ACT is a form of immune therapy that relies on the transfer of tumor-specific T cells that are generally generated by ...

The 5-year survival rate for pancreatic ductal adenocarcinoma (PDA) is currently 13%, making it one of the most fatal human malignancies; to date, PDA is the third leading cause of cancer-related ...

AbstractPurpose:. Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen ...

Endocrine therapy (ET), combined with CDK4/6, mTOR, or PI3K inhibitors, is an effective treatment option for patients with estrogen receptor–positive (ER +)/human epidermal growth factor receptor ...